Regulatory whiplash in dermatology: estimating the hidden cost of isotretinoin guidance reversal
Clicks: 1
ID: 321867
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #162 of 169 articles by views in clinical and experimental dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 169 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
This article estimates the hidden operational and financial cost of repeated isotretinoin regulatory change across UK dermatology services following the MHRAs 2023 and 2026 guidance cycles. Using transparent, conservative assumptions, it argues that substantial clinical, governance, and organisational resource was diverted from patient care and that future regulatory interventions should be evaluated not only for safety intent, but also for implementation burden and opportunity cost.
| Reference Key |
openalex_W7170046856
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | James Denny |
| Journal | clinical and experimental dermatology |
| Year | 2026 |
| DOI |
10.1093/ced/llag316
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.